drugset / Trial / NCT03697850

Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy

NCT03697850 ↗

Phase 2 Active not recruiting 79 enrolled UNICANCER Roche Pharma AG · collab
NaSingle-groupOpen-labelTreatment

Summary

Patients older than ≥18 years, with muscle-invasive bladder cancer unfit for radical cystectomy because of age, comorbidities, and/or patient's refusal. This study is designed as a multicentre, single-arm phase II study.

Timeline

Start
2018-12-14
Primary completion
2025-06-15
Completion
2029-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody 1200 mg Intravenous